These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30857932)

  • 21. A plant-derived VLP influenza vaccine elicits a balanced immune response even in very old mice with co-morbidities.
    Hodgins B; Pillet S; Landry N; Ward BJ
    PLoS One; 2019; 14(1):e0210009. PubMed ID: 30629622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge.
    Herbert AS; Heffron L; Sundick R; Roberts PC
    Virol J; 2009 Apr; 6():42. PubMed ID: 19393093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
    Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of protection against H5N1 influenza virus in mouse offspring provided by maternal vaccination with HA DNA and inactivated vaccine.
    Zhang F; Fang F; Chang H; Peng B; Wu J; Chen J; Wang H; Chen Z
    Arch Virol; 2013 Jun; 158(6):1253-65. PubMed ID: 23385327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice.
    Inn KS; Lee GJ; Quan FS
    Immunol Invest; 2014; 43(3):236-54. PubMed ID: 24354853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of lung CD8
    Moriyama M; Takeyama H; Hasegawa H; Ichinohe T
    Vaccine; 2017 Dec; 35(48 Pt B):6620-6626. PubMed ID: 29079103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of gamma-irradiation conditions on the immunogenicity of whole-inactivated Influenza A virus vaccine.
    David SC; Lau J; Singleton EV; Babb R; Davies J; Hirst TR; McColl SR; Paton JC; Alsharifi M
    Vaccine; 2017 Feb; 35(7):1071-1079. PubMed ID: 28109709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
    J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice.
    Cox RJ; Hovden AO; Brokstad KA; Szyszko E; Madhun AS; Haaheim LR
    Vaccine; 2006 Nov; 24(44-46):6585-7. PubMed ID: 16839650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single immunization with MF59-adjuvanted inactivated whole-virion H7N9 influenza vaccine provides early protection against H7N9 virus challenge in mice.
    Chang H; Duan J; Zhou P; Su L; Zheng D; Zhang F; Fang F; Li X; Chen Z
    Microbes Infect; 2017 Dec; 19(12):616-625. PubMed ID: 28899814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
    Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
    mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection of ferrets from infection by swine-origin 2009 A (H1N1) influenza virus by the inactivated vaccine.
    Shin JS; Do Hwang S; Kim HS; Cho SW; Seo SH
    Viral Immunol; 2010 Aug; 23(4):395-402. PubMed ID: 20712484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-exposure treatment with whole inactivated H5N1 avian influenza virus protects against lethal homologous virus infection in mice.
    Hagan M; Ranadheera C; Audet J; Morin J; Leung A; Kobasa D
    Sci Rep; 2016 Jul; 6():29433. PubMed ID: 27405487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the European Avian-like H1N1 swine influenza virus in mice and pigs.
    Ruan BY; Wen F; Gong XQ; Liu XM; Wang Q; Yu LX; Wang SY; Zhang P; Yang HM; Shan TL; Zheng H; Zhou YJ; Tong W; Gao F; Tong GZ; Yu H
    Vet Microbiol; 2018 Aug; 222():75-84. PubMed ID: 30080677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the pyrogenicity of whole influenza virus particle vaccine in cynomolgus macaques.
    Ohno M; Sagata M; Sekiya T; Nomura N; Shingai M; Endo M; Kimachi K; Suzuki S; Thanh Nguyen C; Nakayama M; Ishigaki H; Ogasawara K; Itoh Y; Kino Y; Kida H
    Vaccine; 2023 Jan; 41(3):787-794. PubMed ID: 36526501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection.
    Handabile C; Sekiya T; Nomura N; Ohno M; Kawakita T; Shingai M; Kida H
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
    Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
    Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.